Antibody drug conjugate development in gastrointestinal cancers:hopes and hurdles from clinical trials  

作　　者：Xiaorong Wu Thomas Kilpatrick Ian Chau 

机构地区：[1]Department of Medical oncology,Royal Marsden Hospital NHS foundation trust,Sutton SM25PT,UK

出　　处：《Cancer Drug Resistance》2018年第4期204-218,共15页癌症耐药（英文）

摘　　要：Gastrointestinal(GI)cancers represent the leading cause of cancer-related mortality worldwide.Antibody drug conjugates(ADCs)are a rapidly growing new class of anti-cancer agents which may improve GI cancer patient survival.ADCs combine tumour-antigen specific antibodies with cytotoxic drugs to deliver tumour cell specific chemotherapy.Currently,only two ADCs[brentuximab vedotin and trastuzumab emtansine(T-DM1)]have been Food and Drug Administration approved for the treatment of lymphoma and metastatic breast cancer,respectively.Clinical research evaluating ADCs in GI cancers has shown limited success.In this review,we will retrace the relevant clinical trials investigating ADCs in GI cancers,especially ADCs targeting human epidermal growth receptor 2,mesothelin,guanylyl cyclase C,carcinogenic antigen-related cell adhesion molecule 5(also known as CEACAM5)and other GI malignancy specific targets.We will review potential hurdles for their success and provide new perspective for future treatment.

关 键 词：Antibody drug conjugates human epidermal growth receptor 2 MESOTHELIN guanylyl cyclase C carcinogenic antigen-related cell adhesion molecule 5 gastric cancer colorectal cancer pancreatic cancer T-DM1 DS-8201a 

分 类 号：R73[医药卫生—肿瘤]